Log in

NASDAQ:AKCA - Akcea Therapeutics Stock Price, Forecast & News

-1.13 (-7.83 %)
(As of 03/30/2020 06:00 AM ET)
Today's Range
Now: $13.31
50-Day Range
MA: $15.76
52-Week Range
Now: $13.31
Volume272,007 shs
Average Volume317,652 shs
Market Capitalization$1.35 billion
P/E Ratio28.94
Dividend YieldN/A
Akcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. operates as a subsidiary of Ionis Pharmaceuticals, Inc.
Read More
Akcea Therapeutics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:AKCA



Sales & Book Value

Annual Sales$488.54 million
Cash Flow$0.51 per share
Book Value$5.78 per share


Net Income$40.77 million


Market Cap$1.35 billion
Next Earnings Date5/13/2020 (Estimated)

Receive AKCA News and Ratings via Email

Sign-up to receive the latest news and ratings for AKCA and its competitors with MarketBeat's FREE daily newsletter.

Akcea Therapeutics (NASDAQ:AKCA) Frequently Asked Questions

How has Akcea Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Akcea Therapeutics' stock was trading at $13.44 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AKCA shares have decreased by 1.0% and is now trading at $13.31. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Akcea Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akcea Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Akcea Therapeutics.

When is Akcea Therapeutics' next earnings date?

Akcea Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for Akcea Therapeutics.

How were Akcea Therapeutics' earnings last quarter?

Akcea Therapeutics Inc (NASDAQ:AKCA) announced its earnings results on Tuesday, February, 25th. The company reported $0.86 earnings per share for the quarter, missing analysts' consensus estimates of $2.10 by $1.24. The firm earned $277.48 million during the quarter, compared to analyst estimates of $225.94 million. Akcea Therapeutics had a return on equity of 10.03% and a net margin of 8.35%. The business's revenue was up 2620.4% on a year-over-year basis. During the same quarter last year, the firm earned ($0.79) EPS. View Akcea Therapeutics' earnings history.

What price target have analysts set for AKCA?

4 brokers have issued 12-month target prices for Akcea Therapeutics' shares. Their forecasts range from $24.00 to $41.00. On average, they anticipate Akcea Therapeutics' share price to reach $34.67 in the next twelve months. This suggests a possible upside of 160.5% from the stock's current price. View analysts' price targets for Akcea Therapeutics.

Has Akcea Therapeutics been receiving favorable news coverage?

News stories about AKCA stock have trended somewhat negative recently, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Akcea Therapeutics earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutAkcea Therapeutics.

Are investors shorting Akcea Therapeutics?

Akcea Therapeutics saw a decrease in short interest during the month of March. As of March 13th, there was short interest totaling 3,366,000 shares, a decrease of 7.0% from the February 27th total of 3,620,000 shares. Based on an average daily volume of 254,300 shares, the days-to-cover ratio is currently 13.2 days. Approximately 36.4% of the shares of the stock are sold short. View Akcea Therapeutics' Current Options Chain.

Who are some of Akcea Therapeutics' key competitors?

What other stocks do shareholders of Akcea Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akcea Therapeutics investors own include Ionis Pharmaceuticals (IONS), Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Achaogen (AKAO), Ciena (CIEN), AMC Entertainment (AMC), Apollo Global Management (APO), Associated British Foods (ABF) and Chaarat Gold (CGH).

Who are Akcea Therapeutics' key executives?

Akcea Therapeutics' management team includes the following people:
  • Ms. Paula Soteropoulos, CEO & Director (Age 51)
  • Mr. Michael F. MacLean, Chief Financial Officer (Age 53)
  • Dr. Louis St. Laurence O'Dea FRCPC, MB, BCh, BAO, FRCP(C), Chief Medical Officer (Age 68)
  • Ms. Sarah Boyce, Pres & Director (Age 47)
  • Mr. Jeffrey M. Goldberg, Chief Operating Officer (Age 46)

When did Akcea Therapeutics IPO?

(AKCA) raised $125 million in an initial public offering on Friday, July 14th 2017. The company issued 9,600,000 shares at a price of $12.00-$14.00 per share. Cowen and Company, Stifel and Wells Fargo Securities acted as the underwriters for the IPO and BMO Capital Markets was co-manager.

What is Akcea Therapeutics' stock symbol?

Akcea Therapeutics trades on the NASDAQ under the ticker symbol "AKCA."

Who are Akcea Therapeutics' major shareholders?

Akcea Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include FMR LLC (11.50%), State Street Corp (0.71%), Point72 Asset Management L.P. (0.27%), Geode Capital Management LLC (0.27%), Charles Schwab Investment Management Inc. (0.16%) and Russell Investments Group Ltd. (0.12%). Company insiders that own Akcea Therapeutics stock include Damien Mcdevitt, Ionis Pharmaceuticals Inc, Jeff Marc Goldberg, Joshua F Patterson, Kyle Jenne, Paula Soteropoulos and Sarah Boyce. View institutional ownership trends for Akcea Therapeutics.

Which institutional investors are selling Akcea Therapeutics stock?

AKCA stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Rafferty Asset Management LLC, Geode Capital Management LLC, ProShare Advisors LLC, Nuveen Asset Management LLC, and Motley Fool Asset Management LLC. Company insiders that have sold Akcea Therapeutics company stock in the last year include Damien Mcdevitt, Jeff Marc Goldberg, Joshua F Patterson, Kyle Jenne, Paula Soteropoulos, and Sarah Boyce. View insider buying and selling activity for Akcea Therapeutics.

Which institutional investors are buying Akcea Therapeutics stock?

AKCA stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Renaissance Technologies LLC, Russell Investments Group Ltd., State Street Corp, Charles Schwab Investment Management Inc., Amia Capital LLP, Virtus ETF Advisers LLC, and California Public Employees Retirement System. View insider buying and selling activity for Akcea Therapeutics.

How do I buy shares of Akcea Therapeutics?

Shares of AKCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Akcea Therapeutics' stock price today?

One share of AKCA stock can currently be purchased for approximately $13.31.

How big of a company is Akcea Therapeutics?

Akcea Therapeutics has a market capitalization of $1.35 billion and generates $488.54 million in revenue each year. The company earns $40.77 million in net income (profit) each year or $0.48 on an earnings per share basis. Akcea Therapeutics employs 248 workers across the globe. View additional information about Akcea Therapeutics.

What is Akcea Therapeutics' official website?

The official website for Akcea Therapeutics is http://www.akceatx.com/.

How can I contact Akcea Therapeutics?

Akcea Therapeutics' mailing address is 22 BOSTON WHARF RD 9TH FLOOR, BOSTON MA, 02210. The company can be reached via phone at 617-207-0202 or via email at [email protected]

MarketBeat Community Rating for Akcea Therapeutics (NASDAQ AKCA)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  333 (Vote Outperform)
Underperform Votes:  346 (Vote Underperform)
Total Votes:  679
MarketBeat's community ratings are surveys of what our community members think about Akcea Therapeutics and other stocks. Vote "Outperform" if you believe AKCA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKCA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/30/2020 by MarketBeat.com Staff

Featured Article: What is a support level?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel